B019 is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. All registered phases are Phase 1. The lead sponsor is Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. The most-studied condition is Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
NCT06927466 · ClinicalTrials.gov ↗ · Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
|
Phase 1 | Recruiting | Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd | China |
|
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
NCT06970496 · ClinicalTrials.gov ↗ · Relapsed or Refractory B Cell Non Hodgkin Lymphoma
|
Phase 1 | Not yet open | Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name B019 as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how B019 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how B019 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists B019 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.